Argon laser photocoagulation treatment in central serous chorioretinopathy

Ophthalmology. 1986 Jul;93(7):972-4. doi: 10.1016/s0161-6420(86)33652-2.

Abstract

Central serous chorioretinopathy, a sporadic self-limited disease of young adults, is associated with loss of central vision, image distortion, and imparied dark adaptation. The diagnosis is verified with fluorescein angiography, which demonstrates and expanding point of fluorescein dye leakage under a serous detachment of the sensory retina. Treatment should ordinarily be delayed four or more months but may be considered if there is evidence of microarchitectural changes in the macular retina, if the best corrected visual acuity declines to 20/40 or less, or if there have been multiple recurrences. Argon laser photocoagulation should be directed to the leakage site, using spot sizes of 200 mu in diameter, exposure times of 0.2 seconds, and low-power intensities.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Argon
  • Clinical Trials as Topic
  • Humans
  • Laser Therapy*
  • Light Coagulation* / methods
  • Middle Aged
  • Retinal Diseases / surgery*

Substances

  • Argon